References of "Zegels, Brigitte"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailDiagnostic efficiency of a self-evaluating risk assessment for postmenopausal osteoporosis
Goemaere, S; Zegels, Brigitte ULg; Toye, K et al

in Calcified Tissue International (1997), 61

Detailed reference viewed: 17 (4 ULg)
Full Text
Peer Reviewed
See detailA 2-year phase II study with 1-year of follow-up of risedronate (NE58095) in postmenopausal osteoporosis
Clemmesen, B; Ravn, P; Zegels, Brigitte ULg et al

in Osteoporosis International (1997), 7

Detailed reference viewed: 9 (4 ULg)
Peer Reviewed
See detailParathyroid Hormone in the Treatment of Involutional Osteoporosis: Back to the Future
Reginster, Jean-Yves ULg; Taquet, A. N.; Fraikin, G. et al

in Osteoporosis International (1997), 7(Suppl 3), 163-8

Detailed reference viewed: 15 (5 ULg)
Full Text
Peer Reviewed
See detailDensité osseuse fémorale et carence vitaminique D dans une population de femmes âgées
DEROISY; Pirenne, H; FREDERICK, Isabelle ULg et al

in Archives of Public Health (1996), 53(S1), 37

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailSodium monofluorophosphate reduces fracture incidence in women with postmenopausal osteoporosis : a randomized, placebo-controlled, double-blind study
Meurmans, L; Zegels, Brigitte ULg; Rovati, LC et al

in Revue du Rhumatisme (English ed.) (1996), 63

Detailed reference viewed: 4 (1 ULg)
Full Text
Peer Reviewed
See detailPrévention de l’ostéoporose à Liège. Histoire d’un PIGEPS : dix ans plus tard.
Reginster, Jean-Yves ULg; DEROISY, Rita ULg; LECART, Marie-Paule ULg et al

in Santé Publique : Revue Multidisciplinaire pour la Recherche et l'Action (1996), 2

Detailed reference viewed: 14 (3 ULg)
Full Text
Peer Reviewed
See detailBiochemical evidence of antiresorptive effect of risedronate in established osteoporosis
Zegels, Brigitte ULg; Taquet, AN; Eastell, R et al

in Osteoporosis International (1996), 6(S1), 249

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailA Double-Blind, Placebo-Controlled, Dose-Finding Trial of Intermittent Nasal Salmon Calcitonin for Prevention of Postmenopausal Lumbar Spine Bone Loss
Reginster, Jean-Yves ULg; Deroisy, Rita ULg; Lecart, M. P. et al

in American Journal of Medicine (1995), 98(5), 452-8

PURPOSE: Nasal administration of salmon calcitonin (SCT) has been suggested for preventing trabecular bone loss during the first years following the menopause, but no conclusive evidence has appeared ... [more ▼]

PURPOSE: Nasal administration of salmon calcitonin (SCT) has been suggested for preventing trabecular bone loss during the first years following the menopause, but no conclusive evidence has appeared about the minimal effective dose. Since nasal calcitonin is highly expensive, it makes sense to define this dose. PATIENTS AND METHODS: We performed a double-blind, placebo-controlled, randomized, single-center study with a 3-arm parallel-group design. The subjects were 251 healthy women who had experienced natural menopause within the past 6 to 72 months and were not affected by any diseases or treatments that interfere with calcium metabolism. They were randomly allocated in groups of 6 to receive intranasal SCT 50 IU (n = 84), SCT 200 IU (n = 84), or placebo (n = 83). All treatments were given on 5 consecutive days per week. Statistical analysis was based on two populations: intention-to-treat (IT) and valid completers (VC). The main assessments performed were bone mineral density of the lumbar spine (LSBMD) and biochemical parameters reflecting bone turnover (serum alkaline phosphatase, urinary calcium/creatinine, and hydroxyproline/creatinine ratios). RESULTS: Changes over the treatment period were comparable in the IT and VC populations. In the group receiving the placebo, LSBMD decreased from baseline to end point by a mean of 6.28% (95% confidence interval [CI] -7.69 to -4.89) in the IT population and 6.98% (95% CI -8.86 to -5.11) in the VC population (P = 0.0001, end LSBMD versus baseline LSBMD). LSBMD increased slightly with the 50-IU/d dose of SCT, by 0.82% (95% CI -0.26 to 1.89) in the IT population, and 0.51% (95% CI -0.69 to 1.72) in the VC (P = NS, versus baseline). Subjects who received SCT 200 IU/d experienced significant increases of 2.03% (95% CI 0.92 to 3.15) in the IT population and 2.26% (95% CI 1.01 to 3.51) in the VC (both P = 0.001). The difference between the evolution of the combined groups receiving nasal SCT and the group treated with the placebo was highly significant (P = 0.0001). No significant changes were recorded in biochemical parameters reflecting bone turnover. CONCLUSIONS: SCT 50 IU/d administered nasally and intermittently appears to prevent lumbar bone loss in nonobese early postmenopausal women. [less ▲]

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailLong-Term Performance in Vitro and in Vivo of Dual-Energy X-Ray Absorptiometry
Reginster, Jean-Yves ULg; Deroisy, Rita ULg; Zegels, Brigitte ULg et al

in Clinical Rheumatology (1995), 14(2), 180-6

Dual-energy X-ray absorptiometry (DXA) is actually considered as one of the most appropriate techniques for measuring bone mineral content (BMC) and bone mineral density (BMD). An anthropomorphic phantom ... [more ▼]

Dual-energy X-ray absorptiometry (DXA) is actually considered as one of the most appropriate techniques for measuring bone mineral content (BMC) and bone mineral density (BMD). An anthropomorphic phantom and a 25-year-old girl were repeatedly measured, 160 times and 50 times respectively, over an 18-month period to investigate performance in vitro and in vivo of a commercial DXA equipment (HOLOGIC QDR 1000). DXA is a highly accurate technique, the BMC and BMD determinations only overestimated the exact value of the phantom by 0.20% and 0.51% respectively. In vivo long-term (18 months) reproducibility of BMD of the spine is characterized by an interassay coefficient of variation (CVt) of 0.8% while, for the different regions of interest of the hip, BMD CVt varies from 1.1% (total zone) to 5.3% (Ward's triangle). In the subject tested, BMD sensitivity for changes of 2.2% at the lumbar spine and 3% at the hip were recorded. [less ▲]

Detailed reference viewed: 7 (4 ULg)
Peer Reviewed
See detailEffect of risedronate on collagen cross-links in postmenopausal osteoporosis
Zegels, Brigitte ULg; Balena, R; Eastell, R et al

in Journal of Bone and Mineral Research (1995), 10(s1), 455

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailFemoral bone density and vitamin D deficiency in elderly women
DEROISY; Pirenne, H; Frederick, I et al

in Archives of Public Health (1995), 52(S1), 81

Detailed reference viewed: 10 (0 ULg)
Full Text
Peer Reviewed
See detailFemoral bone density and vitamin D deficiency in elderly women
DEROISY; Pirenne, H; Frederick, I et al

in Journal of Bone and Mineral Research (1995), 10(S1), 463

Detailed reference viewed: 6 (3 ULg)
Full Text
Peer Reviewed
See detailDensité osseuse fémorale et carence vitaminique D dans une population de femmes âgées
DEROISY; Pirenne, H; Frederick, I et al

in Revue du Rhumatisme (1995), 10

Detailed reference viewed: 5 (3 ULg)
Full Text
Peer Reviewed
See detailBone mineral density of the spine and the hip measured with dual energy X-ray absorptiometry: normal range and fracture threshold for western European (Belgian) postmenopausal females.
Reginster, Jean-Yves ULg; Janssen, C; DEROISY, Rita ULg et al

in Clinical Rheumatology (1995), 14(1), 68-75

Bone mineral density (BMD) of the spine and the different regions of interest (ROI) of the hip were measured by dual energy X-ray absorptiometry in 278 healthy Belgian postmenopausal women and 93 ... [more ▼]

Bone mineral density (BMD) of the spine and the different regions of interest (ROI) of the hip were measured by dual energy X-ray absorptiometry in 278 healthy Belgian postmenopausal women and 93 postmenopausal type I osteoporotic females in order to: a) determine the normal range for lumbar and hip BMD values; b) define an "hypothetical" fracture threshold in this population; c) determine the preferential region to be considered for clinical use in type I osteoporosis. In the normal subjects, there is a negative relationship (< 0.001) between age or time elapsed since menopause (Tm) and BMD measured at the level of the spine or at the ROI of the hip. For the spine, evidence of a curvilinear relationship was assessed. Regressions of BMD at the hip as a function of age or time elapsed since menopause, were best fitted by a linear relationship. In the population of postmenopausal women who have experienced a vertebral crush fracture, no relationships were observed between spine BMD and age or Tm but the osteoporotic women had a spine BMD significantly lower compared to age-matched normal controls: Z-score = -1.2 +/- 0.6 (mean +/- SD) (p < 0.0001). Fracture threshold calculated as the 90th percentile of spine BMD measured in osteoporotic patients was 0.840 g/cm2, corresponding to the mean value -1 SD for a population of women aged 51 years. [less ▲]

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailLong-Term (3 Years) Prevention of Trabecular Postmenopausal Bone Loss with Low-Dose Intermittent Nasal Salmon Calcitonin
Reginster, Jean-Yves ULg; Denis, D.; Deroisy, Rita ULg et al

in Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Research (1994), 9(1), 69-73

The long-term effect of intermittent low-dose nasal salmon calcitonin on trabecular early postmenopausal bone loss was assessed as follow-up to a previously published study. Randomized controlled group ... [more ▼]

The long-term effect of intermittent low-dose nasal salmon calcitonin on trabecular early postmenopausal bone loss was assessed as follow-up to a previously published study. Randomized controlled group comparison was made of 287 healthy women with 6-36 months of natural menopause and no treatment interfering with calcium metabolism at an outpatient clinic for research in bone and cartilage metabolism. The 287 women were randomly allocated to 3 years of treatment with either 500 mg/day, 5 days/week of calcium or the same amount of calcium plus 50 IU/day, 5 days per week of nasal salmon calcitonin. A total of 186 women complied with the study protocol throughout. The main outcome measures were bone mineral density of the lumbar spine (DPA) and biochemical parameters reflecting bone turnover (serum alkaline phosphatases, urinary calcium/creatinine, and hydroxyproline/creatinine ratio). The average changes in bone mineral density after 36 months showed a positive (p < 0.05) outcome (1.8 +/- 5.7%; mean +/- SD) in the group treated with salmon calcitonin and calcium and a significant (p < 0.01) loss (-5.8 +/- 4.8%) in patients receiving calcium alone. The difference between the evolution of the two groups was significantly (p < 0.01) different after 6 months of treatment and remained so until the end of the study. No significant changes were recorded in biochemical parameters reflecting bone turnover. As previously shown during a 1 year follow-up, nasal salmon calcitonin given at low dose and intermittently, in association with calcium, can counteract trabecular postmenopausal bone loss. [less ▲]

Detailed reference viewed: 9 (1 ULg)
Peer Reviewed
See detailAcute biochemical variations induced by four different calcium salts in healthy male volunteers
Reginster, Jean-Yves ULg; Denis, D; Bartsch, V et al

in Equilibre (1994), 19

Detailed reference viewed: 15 (2 ULg)
Full Text
Peer Reviewed
See detailPrevention of Osteoporosis with Nasal Salmon Calcitonin: Effect of Anti-Salmon Calcitonin Antibody Formation
Reginster, Jean-Yves ULg; Gaspar, S; Deroisy, Rita ULg et al

in Osteoporosis International : A Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis & the National Osteoporosis Foundation of the USA (1993), 3

The amino acid sequence of salmon calcitonin (SCT) differs considerably from that of the human hormone and specific antibodies (Ab) develop in a significant proportion of patients after parenteral or ... [more ▼]

The amino acid sequence of salmon calcitonin (SCT) differs considerably from that of the human hormone and specific antibodies (Ab) develop in a significant proportion of patients after parenteral or nasal administration of SCT. Controversy remains regarding the functional importance of these Ab. We report on the development of specific anti-SCT Ab in a population of postmenopausal women receiving nasal SCT for prevention of postmenopausal bone loss, and compare the effects of nasal SCT in women with or without Ab. Thirty-nine per cent of women developed Ab after 6 months of treatment with SCT, 52% after 12 months, and 61% after 18 and 24 months. After 24 months the AB titre was 3.47-17.7 x 10(-9) M/l (mean +/- SD: 13.3 +/- 3.1 x 10(-9) M/l). No significant differences appeared between the changes in lumbar bone mineral density (BMD) measured in the whole population (n = 44) (mean +/- SD: +1.06 +/- 3.9%), the patients without Ab (n = 17) (+0.05 +/- 3.7%) or in those with Ab (n = 27) (+1.7 +/- 4.6%). During the same period, a control population randomly assigned to a 500 mg/day calcium intake showed a significant loss of lumbar BMD (-4.57 +/- 4.9%) (p < 0.01). In conclusion, in healthy postmenopausal women nasal SCT seems to maintain the same preventive effect against bone loss whether or not Ab are present. [less ▲]

Detailed reference viewed: 11 (3 ULg)